fanconi anemia epidemiology forecast

DelveInsight’s ‘Fanconi Anemia – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Fanconi anemia in the United States, EU4 (Germany, Spain, Italy, France) and the UK, and Japan.

Geographies Covered

• The United States
• EU4 and the United Kingdom
• Japan

Study Period: 2021-2034

Fanconi Anemia: Disease Understanding

Fanconi Anemia Overview

As per National Cancer Institute (NCI), Fanconi anemia is a rare inherited disorder in which the bone marrow does not make enough blood cells, including red blood cells, white blood cells, and platelets. It is usually diagnosed before the age of 15 years.

Symptoms include frequent infections, a tendency to bleed easily, and extreme tiredness. People with Fanconi anemia may also have brown spots on the skin, short height, malformed thumbs or forearms, small heads or eyes, hearing loss, and abnormalities of the kidneys, gastrointestinal tract, heart, genitals, brain, and spinal cord. They also have an increased risk of developing certain types of cancer, including leukemia and cancers of the skin, head, neck, gastrointestinal system, and genitals. Fanconi anemia is caused by mutations (changes) in certain genes involved in DNA repair.

An early and accurate diagnosis of Fanconi anemia is often difficult because Fanconi anemia is highly variable genetically and in how it presents in each individual. The following methods are used in diagnosing Fanconi anemia: history and examination, tests and assessments, Fanconi anemia complementation/genetic analysis, skin biopsy, bone marrow examination, imaging, and related tests.

The treatment of Fanconi anemia is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. The therapeutic landscape of Fanconi anemia currently includes supportive treatment like blood transfusions and RBC transfusions, hematopoietic stem cell transplantation (HSCT), androgen therapy, and surgical treatment. At present, the only potentially curative treatment is HSCT. HSCT is associated with high economic costs, and most insurance does not cover stem cell therapy. Currently, no specific medication is approved for treating Fanconi anemia patients, and thus, there is a significant urgent need for more effective and targeted options.

Epidemiology

The Fanconi anemia epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Fanconi anemia epidemiology segmented as the Diagnosed Prevalent Cases of Fanconi Anemia, Mutation-specific Cases of Fanconi Anemia, and Comorbidity Associated with Fanconi Anemia. The report includes the prevalent Fanconi anemia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2021 to 2034.

Country-wise Fanconi Anemia Epidemiology

• The epidemiology segment also provides the Fanconi anemia epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
• The total number of cases of Fanconi anemia in the 7MM countries was more than 6,600 cases in 2021.
• As per the estimates, the United States had the highest prevalent patient population of Fanconi anemia in 2021. Among EU4 and the UK, Germany had the highest number of cases of Fanconi anemia, with more than 700 cases, followed by France in 2021. On the other hand, Spain had the lowest number of cases of Fanconi anemia, with close to 400 cases in 2021.

Scope of the Report

• Fanconi anemia report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
• Fanconi anemia epidemiology report and model provide an overview of the risk factors and global trends of Fanconi anemia in the seven major markets (The 7MM: The US, France, Germany, Italy, Spain, the UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Fanconi anemia in seven major markets covering the United States, EU4 and the UK, and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Fanconi anemia.
• The report provides the segmentation of the Fanconi anemia epidemiology by the diagnosed prevalent cases of Fanconi anemia, mutation-specific cases of Fanconi anemia, and comorbidity associated with Fanconi anemia in the 7MM.

Report Highlights

• 10-year forecast of Fanconi anemia Epidemiology
• The 7MM Coverage
• Diagnosed prevalent cases of Fanconi anemia
• Mutation-specific cases of Fanconi anemia
• Comorbidity associated with Fanconi anemia

KOL Views

We interview KOLs and obtain SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern, and this will support the clients in potential novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

• What major factors will drive the change in the patient population in an indication of Fanconi anemia during the forecast period (2025-2034)?
• What key findings about Fanconi anemia epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period (2025-2034)?
• What would be the total number of patients with Fanconi anemia across the 7MM forecast period (2025-2034)?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2025-2034)?
• What are the disease risk, burdens, and unmet needs of Fanconi anemia?
• What currently available treatments for Fanconi anemia?

Reasons to buy

Fanconi anemia epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Fanconi anemia market.
• Quantify patient populations in the global Fanconi anemia market to improve product design, pricing, and launch plans.
• Understand the magnitude of the Fanconi anemia population by its diagnosed prevalent cases, mutation-specific cases, and comorbidity associated with Fanconi anemia.
• The Fanconi anemia epidemiology report and model were written and developed by Masters and PhD epidemiologists.
• The Fanconi anemia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population